Increased circulating immunosuppressive CD14+HLA-DR-/low cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1381-1391

  Yuan, X K ^a   Zhao, X K ^a   Xia, Y C ^a   Zhu, X ^a   Xiao, P ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bladder carcinoma; Myeloid derived suppressor cells; Tumour evasion

Indexed keywords

ARGININE; CD14 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENDER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR VOLUME;

EID: 80052194777     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900424     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Järvinen R, Kaasinen E, Sankila A, et al for the FinnBladder Group: Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009; 56: 260-265.
3. Malmström PU, Sylvester RJ, Crawford DE, et al: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscleinvasive bladder cancer. Eur Urol 2009; 56: 247-256.
4. Whiteside TL: Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010; 10: 1019-1035.
5. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
6. Diaz-Montero CM, Salem ML, Nishimura MI, et al: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemo therapy. Cancer Immunol Immunother 2009; 58: 49-59.
7. Li H, Han Y, Guo Q, et al: Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol 2009; 182: 240-249.
8. Pan PY, Ma G, Weber KJ, et al: Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
9. Serafini P, Mgebroff S, Noonan K, et al: Myeloidderived suppressor cells promote cross- tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
10. Youn JI, Nagaraj S, Collazo M, et al: Subsets of myeloid-derived suppressor cells in tumorbearing mice. J Immunol 2008; 181: 5791-5802.
11. Movahedi K, Guilliams M, Van den Bossche J, et al: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
12. Ochoa AC, Zea AH, Hernandez C, et al: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s-726s.
13. Almand B, Clark JI, Nikitina E, et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
14. Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-4760.
15. Zea AH, Rodriguez PC, Atkins MB, et al: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
16. Filipazzi P, Valenti R, Huber V, et al: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-2553.
17. hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-4345.
18. + T cells. Gastroenterology 2008; 135: 234-243.
19. lo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010; 12: 631-644.
20. Gordon IO, Freedman RS: Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res 2006; 12: 1515-1524.
21. low/- monocytes in prostate cancer. Prostate 2010; 70: 443-455.
22. Sobin LH, Wittekind C (eds) for the International Union Against Cancer: Urological tumours: bladder. In: TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002.
23. Mostofi FK, Sobin LH, Torloni H: Histological typing of urinary bladder tumors. In: International Classification of Tumors No 10. Geneva: World Health Organization, 1973.
24. Sinha P, Clements VK, Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174: 636-645.
25. Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-41.
26. Young MR, Newby M, Wepsic HT: Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987; 47: 100-105.
27. Young MR, Aquino S, Young ME: Differential induction of hematopoiesis and immune suppressor cells in the bone marrow versus in the spleen by Lewis lung carcinoma variants. J Leukoc Biol 1989; 45: 262-273.
28. Hoechst B, Voigtlaender T, Ormandy L, et al: Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50: 799-807.
29. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
30. + myeloid cells. Cancer Res 2006; 66: 6807-6815.
31. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
32. low/- regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009; 131: 109-118.
33. + regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319: 41-52.